Micro- and macrovascular treatment targets in scleroderma heart disease

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 536-544

  Dimitroulas, Theodoros ^a   Giannakoulas, George ^b   Karvounis, Haralambos ^b   Garyfallos, Alexandros ^c   Settas, Lucas ^b   Kitas, George D ^a,d  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c Aristotle University of Thessaloniki   (Greece)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiac involvement; Myocardium; Pulmonary arterial hypertension; Small coronary artery disease; Systemic sclerosis; Tissue Doppler

Indexed keywords

ANTICOAGULANT AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IVABRADINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; VASODILATOR AGENT;

ARTICLE; AUTONOMIC NEUROPATHY; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY SPASM; DISEASE ASSOCIATION; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FAILURE; HUMAN; IATROGENIC DISEASE; MICROCIRCULATION; MICROVASCULATURE; MYOCARDIAL DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK MANAGEMENT; SCLERODERMA; SCLERODERMA HEART DISEASE; SYSTEMATIC REVIEW;

CARDIOTONIC AGENTS; CORONARY VESSELS; HEART; HEART DISEASES; HUMANS; MICROVESSELS; MOLECULAR TARGETED THERAPY; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 84894084959     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990555     Document Type: Article

References (130)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum1990; 23: 581-90.
2. Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev 2011; 10: 693-701.
3. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am 1996; 22: 841-60.
4. Ferri C, Giuggioli D, Sebastiani M, Colaci M, Emdin M. Heart involvement and systemic sclerosis. Lupus 2005; 14: 702-7.
5. Boueiz A, Mathai SC, Hummers LK, Hassoun PM. Cardiac complications of systemic sclerosis: recent progress in diagnosis. Curr Opin Rheumatol 2010; 22: 696-703.
6. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
7. Poormoghim H, Lakeh MM, Mohammadipour M, Talehy-Moineddin S, Sodagari F. Pulmonary survival study in 91 patients with systemic sclerosis. Rheumatol Int 2011; 31: 1577-82.
8. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients Ann. Rheum Dis 2010: 69: 218-21.
9. Perera A, Fertig N, Lucas M, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-6.
10. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
11. Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K. Retrospective study of clinical and laboratory features in Japanese scleroderma patients with cardiac involvement. J Dermatol Sci 2009; 55: 70-2.
12. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007; 6: 520-3.
13. Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 2010; 28: S48-53.
14. Ngian GS, Sahhar J, Wicks IP, Van Doornum S. Cardiovascular disease in systemic sclerosis-an emerging association? Arthritis Res Ther 2011; 13: 237.
15. de Groote P, Gressin V, Hachulla E, et al; ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31-6.
16. Nakajima K, Matsuo S, Hasegawa M, Kinuya S, Takehara K. Identification of myocardial damage in systemic sclerosis: a nuclear cardiology approach. Int J Rheumatol 2010; 2010: pii: 496509.
17. Follansbee WP, Miller TR, Curtiss EI, et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990; 17: 656-62.
18. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfá ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003; 9: 311-7.
19. Dimitroulas T, Mavrogeni S, Kitas GD. Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. Nat Rev Rheumatol 2012; 8: 203-13.
20. Rosato E, Maione S, Vitarelli A, et al. Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables. Rheumatol Int 2009; 29: 913-9.
21. Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas G. B-type natriuretic peptide in rheumatic diseases: A cardiac biomarker or a sophisticated acute phase reactant? Autoimmun Rev 2012; 11: 837-43.
22. Schioppo T, Artusi C, Ciavarella T, et al. N-TproBNP as Biomarker in Systemic Sclerosis. Clin Rev Allergy Immunol 2012; 43: 292-301.
23. James TN. De subitaneis mortibus. VIII. Coronary arteries and conduction system in scleroderma heart disease. Circulation 1974; 50: 844-56.
24. Shahane A. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int 2013; 33: 1655-67.
25. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54(Suppl 1): S10-9.
26. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11.
27. Overbeek MJ, Mouchaers KT, Niessen HM, et al. Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. Int J Rheumatol 2010; 2010. pii: 604615.
28. Kahan A, Nitenberg A, Foult JM, et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985; 28: 637-46.
29. Follansbee WP, Curtiss EI, Medsger TA Jr, Owens GR, Steen VD, Rodnan GP. Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma Am J Med 1984; 77: 489-96.
30. Sulli A, Ghio M, Bezante GP, et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 505-9.
31. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976; 53: 483-90.
32. Follansbee WP, Curtiss EI, Medsger TA Jr, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984; 310: 142-8.
33. Vacca A, Siotto P, Cauli A, et al. Absence of epicardial coronary stenosis in patients with systemic sclerosis with severe impairment of coronary flow reserve. Ann Rheum Dis 2006; 65: 274-5.
34. Pintér T, Faludi R, Magyari B, et al. Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. Rheumatology (Oxford) 2011; 50: 781-8.
35. Lekakis J, Mavrikakis M, Emmanuel M, et al. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis. Clin Exp Rheumatol 1998; 16: 135-40.
36. Ishida R, Murata Y, Sawada Y, Nishioka K, Shibuya H. Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun 2000; 21: 729-34.
37. Champion, H. C. The heart in scleroderma. Rheum Dis Clin North Am 2008; 34: 181-90.
38. Alexander EL, Firestein GS, Weiss JL, et al. Reversible coldinduced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986; 105: 661-8.
39. Gustafsson R, Mannting F, Kazzam E, Waldenström A, Hällgren R. Cold-induced reversible myocardial ischaemia in systemic sclerosis. Lancet 1989; 2: 475-9.
40. Long A, Duffy G, Bresnihan B. Reversible myocardial perfusion defects during cold challenge in scleroderma. Br J Rheumatol 1986; 25: 158-61.
41. Steen VD, Follansbee WP, Conte CG, Medsger TA Jr. Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 1996; 39: 677-81.
42. Mizuno R, Fujimoto S, Saito Y, Nakamura S. Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of longterm left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study. Eur J Heart Fail 2010; 12: 268-75.
43. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993; 125: 194-203.
44. Hegedüs I, Czirják L. Left ventricular wall motion abnormalities in 80 patients with systemic sclerosis. Clin Rheumatol 1995; 14: 161-4.
45. Kazzam E, Caidahl K, Hällgren R, Gustafsson R, Landelius J, Waldenström A. Non-invasive assessment of systolic left ventricular function in systemic sclerosis. Eur Heart J 1991; 12: 151-6.
46. Desai CS, Lee DC, Shah SJ. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011; 23: 545-54.
47. Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 2010; 37: 993-9.
48. Can I, Onat AM, Aytemir K, et al. Detecting subclinical biventricular impairment in scleroderma patients by use of pulsed-wave tissue Doppler imaging. Tex Heart Inst J 2009; 36: 31-7.
49. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68: 1878-84.
50. Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol 2012; 30 (2 Suppl 71): S30-7.
51. Kepez A, Akdogan A, Sade LE, et al. Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. Echocardiography 2008; 25: 191-7.
52. Güllülü S, Kaderli AA, Ekbul A, et al. Tissue Doppler echocardiography and myocardial performance index in patients with scleroderma. J Int Med Res 2005; 33: 417-24.
53. Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 2010; 29: 957-64.
54. Lee SW, Choi EY, Jung SY, Choi ST, Lee SK, Park YB. E/E' ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in patients with systemic sclerosis. Clin Exp Rheumatol 2010; 28: S12-7.
55. Plazak W, Zabinska-Plazak E, Wojas-Pelc A, et al. Heart structure and function in systemic sclerosis. Eur J Dermatol 2002; 12: 257-62.
56. Nakajima K, Taki J, Kawano M, et al. Diastolic dysfunction in patients with systemic sclerosis detected by gated myocardial perfusion SPECT: an early sign of cardiac involvement. J Nucl Med 2001; 42: 183-8.
57. Schattke S, Knebel F, Grohmann A, et al. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. Cardiovasc Ultrasound 2010; 8: 3.
58. Roberts NK, Cabeen WR Jr, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 1981; 94: 38-40.
59. Ferri C, Emdin M, Giuggioli D, et al. Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol 1997; 36: 669-76.
60. Bienias P, Ciurzyński M, Korczak D, et al. Pulmonary hypertension in systemic sclerosis determines cardiac autonomic dysfunction assessed by heart rate turbulence. Int J Cardiol 2010; 141: 322-5.
61. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-8.
62. Phung, S. Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682-91.
63. Mathai SC, Hassoun PM. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med 2011; 5: 267-79.
64. Clements PJ, Tan M, McLaughlin VV, et al. Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAHQuERI) Investigators. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71: 249-52.
65. Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. Curr Pharm Des 2012; 18: 1457-64.
66. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-50.
67. Vogel-Claussen J, Skrok J, Shehata ML, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 2011; 258: 119-27.
68. Dimitroulas T, Giannakoulas G, Karvounis H, et al. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 2007; 121: 135-7.
69. Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis MA, Settas L. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2010; 39: 278-84
70. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in sclerodermarelated pulmonary hypertension. Eur Respir J 2010; 35: 95-104.
71. Hsiao SH, Lee CY, Chang SM, Lin SK, Liu CP. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 2006; 19: 507-14.
72. Overbeek MJ, Lankhaar JW, Westerhof N, et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 31: 1160-6.
73. Huez S, Roufosse F, Vachiéry JL, et al. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? Eur Respir J 2007; 30: 928-36.
74. Mahmud M, Champion HC. Right ventricular failure complicating heart failure: pathophysiology, significance, and management strategies. Curr Cardiol Rep 2007; 9: 200-8.
75. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77.
76. Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8: 663-7.
77. Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012; 18: 1465-77.
78. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011; 10: 259-66.
79. Zakopoulos NA, Kotsis VT, Gialafos EJ, et al. Systemic sclerosis is not associated with clinical or ambulatory blood pressure. Clin Exp Rheumatol 2003; 21: 199-204.
80. Hettema ME, Zhang D, de Leeuw K, et al. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 2008; 10: R49.
81. Lippi G, Caramaschi P, Montagnana M, Salvagno GL, Volpe A, Guidi G. Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. Clin Chim Acta 2006; 364: 345-8.
82. Borba EF, Borges CT, Bonfá E. Lipoprotein profile in limited systemic sclerosis. Rheumatol Int 2005; 25: 379-83.
83. Lewandowska K, Ciurzynski M, Gorska E, et al. Antiendothelial cells antibodies in patients with systemic sclerosis in relation to pulmonary hypertension and lung fibrosis. Adv Exp Med Biol 2013; 756: 147-53.
84. Pignone A, Scaletti C, Matucci-Cerinic M, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998; 16: 527-32.
85. Del Papa N, Quirici N, Scavullo C, et al. Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis. J Rheumatol 2010; 37: 2053-63.
86. Derk CT, Jimenez SA. Acute myocardial infarction in systemic sclerosis patients: a case series. Clin Rheumatol 2007; 26: 965-8.
87. Akram MR, Handler CE, Williams M, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford). 2006; 45: 1395-8.
88. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-40.
89. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995; 54: 853-5.
90. Ho M, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000; 59: 39-43.
91. Dick EA, Aviv R, Francis I, et al. Catheter angiography and angioplasty in patients with scleroderma. Br J Radiol 2001; 74: 1091-6.
92. Liu J, Zhang Y, Cao TS, et al. Preferential macrovasculopathy in systemic sclerosis detected by regional pulse wave velocity from wave intensity analysis: comparisons of local and regional arterial stiffness parameters in cases and controls. Arthritis Care Res (Hoboken) 2011; 63: 579-87.
93. Roustit M, Simmons GH, Baguet JP, Carpentier P, Cracowski JL. Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol 2008; 35: 1576-83.
94. Bartoli F, Blagojevic J, Bacci M, et al. Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 2007; 1108: 283-90.
95. Sherer Y, Cerinic MM, Bartoli F, et al. Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann N Y Acad Sci 2007; 1108: 259-67.
96. Vettori S, Maresca L, Cuomo G, Abbadessa S, Leonardo G, Valentini G. Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. Scand J Rheumatol 2010; 39: 485-9.
97. Sfikakis PP, Papamichael C, Stamatelopoulos KS, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007; 56: 1985-93.
98. Rossi P, Granel B, Marziale D, Le Mée F, Francès Y. Endothelial function and hemodynamics in systemic sclerosis. Clin Physiol Funct Imaging 2010; 30: 453-9.
99. D'Andrea A, Stisi S, Caso P, et al. Associations between left ventricular myocardial involvement and endothelial dysfunction in systemic sclerosis: noninvasive assessment in asymptomatic patients. Echocardiography 2007; 24: 587-97.
100. Andersen GN, Mincheva-Nilsson L, Kazzam E, et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002; 46: 1324-32.
101. Cypiene A, Laucevicius A, Venalis A, et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 2008; 27: 1517-22.
102. Timar O, Soltesz P, Szamosi S, Der H, Szanto S, Szekanecz Z, Szucs G. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. J Rheumatol 2008; 35: 1329-33.
103. Peled N, Shitrit D, Fox BD, et al. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol 2009; 36: 970-75.
104. Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology (Oxford) 2008; 47: 578-83.
105. Mok MY, Lau CS, Chiu SS, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum 2011; 63: 1387-95.
106. Khurma V, Meyer C, Park GS, et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum 2008; 59: 591-7.
107. Man A, Zhu Y, Zhang Y, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis 2013; 72: 1188-93.
108. Ngian GS, Sahhar J, Proudman SM, Stevens W, Wicks IP, Van Doornum S. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 2012; 71: 1980-3.
109. Komocsi A, Pinter T, Faludi R, et al. Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2010; 69: 202-05.
110. Au Au K, Singh MK, Bodukam V, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum 2011; 63: 2078-90.
111. Mavrogeni S, Dimitroulas T, Kitas GD. Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. Autoimmun Rev 2012; 12: 305-12.
112. Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD. Biomarkers in systemic sclerosis-related pulmonary arterial hypertension. Curr Vasc Pharmacol 2011; 9: 213-9.
113. Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of Endothelial Dysfunction and Cardiovascular Risk in Patients with Systemic Rheumatic Diseases. Int J Mol Sci 2012; 13: 12315-35.
114. Mouthon L. SSc in 2011: From mechanisms to medicines. Nat Rev Rheumatol 2012; 8: 72-4.
115. Vignaux O, Allanore Y, Meune C, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005; 64: 1268-73.
116. Duboc D, Kahan A, Maziere B, et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum 1991; 34: 198-203.
117. Kahan A, Devaux JY, Amor B, et al. Nicardipine improves myocardial perfusion in systemic sclerosis. J Rheumatol. 1988; 15: 1395-400.
118. Kahan A, Devaux JY, Amor B, et al. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 1990; 47: 483-9.
119. Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 2006; 33: 2464-9.
120. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007; 34: 2423-30.
121. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-8.
122. Colaci M, Sebastiani M, Giuggioli D, et al. Cardiovascular risk and prostanoids in systemic sclerosis. Clin Exp Rheumatol 2008; 26: 333-6.
123. Dorfmüller P, Montani D, Humbert M. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2010; 35: 6-8.
124. Correale M, Montrone D, Ieva R, Di Biase M, Brunetti ND. Ivabradine in systemic sclerosis related pulmonary arterial hypertension. Eur J Intern Med 2012; 23: e210-1.
125. Kumar U, Gokhle SS, Sreenivas V, Kaur S, Misra D. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Rheumatol Int 2013; 33: 1047-52.
126. Topal AA, Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int 2013; 33: 1-18.
127. Mathai, S. C, Hassoun, P. M. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr. Opin. Rheumatol 2009; 21: 642-8.
128. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48(Suppl 3): iii45-8.
129. Bernardo P, Conforti ML, Bellando-Randone S, et al. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. J Rheumatol 2011; 38: 1617-21.
130. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70: 8-14.